Format

Send to

Choose Destination
Arch Ophthalmol. 2011 Jul;129(7):840-6. doi: 10.1001/archophthalmol.2011.143.

Grating visual acuity results in the early treatment for retinopathy of prematurity study.

Collaborators (223)

Madan A, Ball M, Hall JY, Good WV, Good WV, Gancasz J, Durand D, Slagle T, Smith G, Shapiro M, Santiago N, Bhat R, Kaufman L, Miller M, Mittelman D, Neely D, Hynes EA, Plager D, Barr CC, Bottorff M, Whittington GK, Fishman PH, Rychwalski PJ, Gordon RA, Neff DS, Diamond JG, Gill WL, Preslan MW, Powdrill K, Hutcheson KA, Jones E, Steidl SM, Waeltermann JM, Repka MX, Shepard JA, Donahue P, Aucott SW, Collins ML, Gilmore MM, Handa JT, VanderVeen DK, Mansfield T, MacKinnon B, Cole CH, Fraioli A, Hunter D, McCabe O, Petersen R, Strominger MB, MacKinnon S, Johnson R, Tyedmers M, Baker J, Cumming K, Manatrey P, Bedard MP, Casabar R, Capone A, O'Malley E, Rao R, Roarty J, Trese M, Williams G, Summers CG, Cook S, Holleschau A, Maxwell M, Christiansen SP, Brasel D, Davitt BV, Breuer L, Cruz O, Keenan W, Mantych G, Lueder G, Freedman S, Wallace D, Parkman LH, Jones SK, Enyedi L, Goldstein RF, Reynolds JD, Ziemann K, Albert GP, Awner S, Ryan R, Weber PA, Horowitz M, Behrendt C, Combs A, Dweck N, Koty R, LaGamma E, Marmor M, Flynn J, Coki O, Chiang M, Kane S, Krauss A, Lee TC, Lopez RF, Polin R, Phelps DL, Horihan C, Phillips J, Markowitz G, Merriam W, Noel LP, Tingley D, Gearinger M, Rogers GL, Bremer D, Fellows R, Klamfoth S, Arthur B, Cassady CB, Golden R, McGregor ML, Siatkowski RM, Harris C, Yazdanipanah V, Bradford RH, Leonard RE, McCaffree MA, Wheeler DT, Dolphin N, Palmer EA, Stout A, Nichols B, Epley D, Quinn GE, Koh JG, Letterio M, Abbasi S, Edmond JC, Forbes BJ, Maguire AM, Mills MD, Pierce EA, Young TL, Davidson S, Cheng K, Kelchner-Cheng J, Jones J, Bergren R, Doft B, Lobes L, Olsen K, Saunders RA, Purohit D, Stevens L, Lenhart K, Coats DK, Parker ML, Castanes M, Brown A, Edmond J, Garcia-Prats J, Holz E, Jarriel WS, Johnson K, Mandy G, Paysee EA, Rainey AM, Steinkuller PG, Yen KG, Stokes JP, Trigo Y, Gong AK, van Heuven W, Hoffman R, Bracken S, Harrison DY, Bernstein P, King J, Teske M, Redford M, Mowery RL, Everett DF, Good WV, Quintos M, Hardy RJ, Tung B, Tsai G, Dobson V, Hargadon DD, Wood J, Quinn GE, Harvey EM, Connett J, Donovan EF, Hillis A, Holmes JM, Miller JM, Taylor CR, Good WV, Hardy RJ, Redford M, Good WV, Hardy RJ, Dobson V, Palmer EA, Phelps DL, Redford M, van Heuven W, Barr C, Gaynon M, Shapiro M, Wallace D, Davitt BV, Fellows R, Jones J, Cumming K, Neff DS, Shepard JA, Dolphin N, Good V, Hardy RJ, Dobson V, Palmer EA, Phelps DL, Quintos M, Tung B.

Abstract

OBJECTIVE:

To compare grating (resolution) visual acuity at 6 years of age in eyes that received early treatment (ET) for high-risk prethreshold retinopathy of prematurity (ROP) with that in eyes that underwent conventional management (CM).

METHODS:

In a randomized clinical trial, infants with bilateral, high-risk prethreshold ROP (n = 317) had one eye undergo ET and the other eye undergo CM, with treatment only if ROP progressed to threshold severity. For asymmetric cases (n = 84), the high-risk prethreshold eye was randomized to ET or CM.

MAIN OUTCOME MEASURE:

Grating visual acuity measured at 6 years of age by masked testers using Teller acuity cards.

RESULTS:

Monocular grating acuity results were obtained from 317 of 370 surviving children (85.6%). Analysis of grating acuity results for all study participants with high-risk prethreshold ROP showed no statistically significant overall benefit of ET (18.1% vs 22.8% unfavorable outcomes; P = .08). When the 6-year grating acuity results were analyzed according to a clinical algorithm (high-risk types 1 and 2 prethreshold ROP), a benefit was seen in type 1 eyes (16.4% vs 25.2%; P = .004) undergoing ET, but not in type 2 eyes (21.3% vs 15.9%; P = .29).

CONCLUSION:

Early treatment of eyes with type 1 ROP improves grating acuity outcomes, but ET for eyes with type 2 ROP does not. APPLICATION TO CLINICAL MEDICINE: Type 1 eyes should be treated early; however, based on acuity results at 6 years of age, type 2 eyes should be cautiously monitored for progression to type 1 ROP. Trial Registration clinicaltrials.gov Identifier: NCT00027222.

PMID:
21746974
PMCID:
PMC4374597
DOI:
10.1001/archophthalmol.2011.143
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center